Article Sidebar
Published:
Nov 20, 2020Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Neuroprotective and anti-inflammatory effects of myricetin 3-glucoside in a rat model of cerebral ischemia
Abstract
Purpose: To investigate the effect of myricetin 3-glucoside (M3GLS) on middle cerebral artery occlusion (MCAO)-induced cerebral ischemia in a rat model, and the mechanism of action involved.
Methods: A cerebral ischemia rat model was established using MCAO under 10 % chloral hydrate anesthesia. Neurological severity score was determined by analyzing reflex, motor and sensory functions, as well as balancing potential. Infarction volume was determined using triphenyl tetrazolium chloride dye, while counting of Nissl bodies was done after toluidine blue staining. The protein expression levels of Bax and Bcl-2 were assayed using western blotting, while cytokine levels were determined by enzyme-linked immunosorbent assay (ELISA).
Results: Treatment of cerebral ischemia rats with M3GLS effectively reduced infarct volume, when compared to vehicle-treated group (p < 0.05). Moreover, M3GLS treatment significantly increased the population of Nissl bodies and effectively improved neurologic scores (p < 0.05). In M3GLS-pretreated rats, cerebral ischemia-induced elevation of protein expressions of TNF-α, IL-6 and IL-1β were significantly suppressed. M3GL treatment significantly reversed cerebral ischemia-mediated downregulation of Bcl-2 protein level, but markedly reduced cerebral ischemia-induced upregulation of Bax protein level (p < 0.05).
Conclusion: M3GLS exerts protective effect against cerebral ischemia-induced brain injury in rats via downregulation of inflammatory cytokines. It reduces infarction volume in the brain of cerebral ischemia rats, and regulates Bcl-2/Bax protein ratio. Thus, M3GLS has a potential for use in the clinical management of cerebral ischemia.
Keywords: Myricetin, Neuroprotection, Anti-inflammation, Cerebral ischemia, Cytokines, Infarction
